Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96271 | 0.84 | GBA1 (0.41) | GBA1SMYD3ALDH1A1HRH3 | |
| SCHEMBL96666 | 0.78 | GBA1 (0.38) | GBA1CYP2D6ALDH1A1HRH3 | |
| SCHEMBL23867318 | 0.77 | GBA1 (0.49) | GBA1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18775521 | 0.75 | GBA1 (0.36) | GBA1SMYD3 | |
| SCHEMBL26157412 | 0.75 | GBA1 (0.36) | GBA1SMYD3ALDH1A1 | |
| SCHEMBL8183912 | 0.73 | GBA1 (0.35) | GBA1SMYD3 | |
| Hydrochloric Acid SCHEMBL31719955 | 0.73 | GBA1 (0.35) | GBA1 | |
| SCHEMBL23588763 | 0.73 | DRD2 (0.37) | GBA1SLC6A2SLC6A3KCNH2 | |
| SCHEMBL7799387 | 0.73 | GBA1 (0.35) | GBA1SMYD3 | |
| SCHEMBL14967796 | 0.73 | GBA1 (0.35) | GBA1SMYD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-0710662-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | MAP3K1, PIK3CA, MAP3K5 | GBA1 3031/4885CYP2D6 4262/4885SLC6A2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.